260 results on '"Shipley, W.U."'
Search Results
2. Genomic Determinants of Response to Trimodality Therapy for Muscle-Invasive Bladder Cancer
3. Multi-Institutional Matched Comparison of Radical Cystectomy to Trimodality Therapy for Muscle Invasive Bladder Cancer (MIBC)
4. Validation of a 22-gene Genomic Classifier in the NRG Oncology/RTOG 9202, 9413 and 9902 Phase III Randomized Trials: A Biopsy-Based Individual Patient Meta-Analysis in High-Risk Prostate Cancer
5. Impact of High DosE rAdioTherapy (HEAT) in Localized Prostate Cancer: An Individual Patient Data (IPD) Meta-Analysis of 15 Randomized Trials
6. Individual Patient Data Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium: Impact of Androgen Deprivation Therapy Use and Duration With Definitive Radiotherapy for Localized Prostate Cancer
7. NRG Oncology/RTOG 0926: Phase II Protocol for Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent With Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging
8. Metastasis-Free Survival, but Not Biochemical Failure, is a Strong Surrogate Endpoint for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601
9. Mutational Landscape and Genetic Determinants of Response to Trimodality Therapy in Muscle-Invasive Bladder Cancer
10. Short-Term Adjuvant versus Neoadjuvant Hormone Therapy in Localized Prostate Cancer: A Pooled Individual Patient Analysis of Two Randomized Phase 3 Trials
11. Bladder Preservation with Twice-Daily Radiation plus 5-Flourouracil/Cisplatin or Daily Radiation plus Gemcitabine for MIBC – Updated Results of NRG/RTOG 0712: A Randomized Phase 2 Trial
12. The Impact of Persistently Elevated PSA after Prostatectomy in Men with Recurrent Prostate Cancer in NRG Oncology/RTOG 9601
13. 10-Year Outcome for Men With Localized Prostate Cancer Treated With External Radiation Therapy:: Results of a Cohort Study
14. Prostate Cancer DNA Ploidy and Response to Salvage Hormone Therapy After Radiotherapy With or Without Short-Term Total Androgen Blockade: An Analysis of RTOG 8610
15. Two Years of Anti-Androgen Treatment Increases Other-Cause Mortality in Men Receiving Early Salvage Radiotherapy: A Secondary Analysis of the NRG Oncology/RTOG 9601 Randomized Phase III Trial
16. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer
17. The value of external beam radiation in node positive prostate cancer: a multivariate analysis
18. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder
19. Androgen Receptor Activity and Radiotherapeutic Sensitivity in African-American Men with Prostate Cancer: A Large Scale Gene Expression Analysis and Meta-Analysis of RTOG Trials
20. Comparative Effectiveness of Bladder-Preserving Tri-Modality Therapy versus Radical Cystectomy for Muscle-Invasive Bladder Cancer
21. Long-Term Update of NRG Oncology RTOG 94-08
22. OC-0057: Randomized phase 2 trial of radiation with either gemcitabine or 5FU/cisplatin in bladder cancer
23. Selective Bladder Preservation with Twice-Daily Radiation Plus 5-Flourouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Patients with Muscle Invasive Bladder Cancer—Primary Results of NRG/RTOG 0712: A Randomized Phase 2 Multicenter Trial
24. Outcomes and Tolerability of Selective Bladder Preservation by Combined Modality Therapy for Invasive Bladder Cancer in Elderly Patients
25. Subtyping Muscle-Invasive Bladder Cancer to Assess Clinical Response to Trimodality Therapy
26. The Impact of MRE11 in Nuclear to Cytoplasmic Ratio on Outcomes in Muscle Invasive Bladder Cancer: an Analysis of NRG/RTOG 8802, 8903, 9506, 9706, 9906, and 0233.
27. Treatment Patterns and Outcomes of Nonurothelial Cell Carcinoma of the Bladder: Results From the National Cancer Data Base
28. Clinical Outcomes of Combined Modality Bladder-Sparing Therapy for Patients With Histologic Variants of Bladder Cancer
29. The Natural History of Nonmuscle-Invasive Bladder Cancer Recurrences After Complete Response to Combined-Modality Organ-Preserving Therapy for Muscle-Invasive Bladder Cancer
30. Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-Term Results of a Large Institutional Experience
31. The role of neoadjuvant or adjuvant chemotherapy for invasive bladder cancer: Is there a benefit for survival or preserving the bladder?
32. Report of NRG Oncology/RTOG 9601, A Phase 3 Trial in Prostate Cancer: Anti-androgen Therapy (AAT) With Bicalutamide During and After Radiation Therapy (RT) in Patients Following Radical Prostatectomy (RP) With pT2-3pN0 Disease and an Elevated PSA
33. Long-term Results of Early Salvage Versus Adjuvant Postprostatectomy Radiation: A Large Institutional Experience
34. Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer
35. Long-term Outcomes After Bladder-Preserving Combined Modality Therapy for Patients With Muscle-Invasive Bladder Cancer
36. Novel Predictive MicroRNA Signature in the Setting of Selective Trimodality Bladder Preservation Therapy
37. Presentation, Treatment, and Outcomes for Bladder Cancer Patients With Nonurothelial Histologies Treated by Radical Cystectomy: Implications for Adjuvant Radiation Therapy
38. Feasibility of Gene Expression Signature Analysis in Prostate Cancer Biopsy Specimens to Predict Outcomes Following Radiation Therapy
39. Outcomes of Selective Bladder Preservation in the Elderly Treated With Conservative Surgery and Chemoradiation
40. Radiation Therapy Oncology Group (RTOG) 9413: A Randomized Trial Comparing Whole Pelvic Radiation Therapy (WPRT) to Prostate Only (PORT) and Neoadjuvant Hormonal Therapy (NHT) to Adjuvant Hormonal Therapy (AHT)
41. Multimodality Management in Primary Urethral Cancer: The Role of Radiation Therapy
42. Acute and Late Urinary Toxicity After Radiation Therapy in Men With and Without an Intact Prostate Gland: A Secondary Analysis of RTOG 9408 and 9601 Suggesting This Toxicity is Not Due to Bladder Injury
43. Utilization of Potentially Curative Therapies for Muscle Invasive Bladder Cancer: Results From the National Cancer Data Base
44. Factors Associated With Clinical-Pathologic Stage Discrepancy in Bladder Cancer Patients Treated With Radical Cystectomy: Implications for Treatment Selection and Comparative Studies
45. Long-term Outcomes After Bladder Preserving Combined Modality Therapy for Muscle-invasive Bladder Cancer: A Pooled Analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233
46. Cardiovascular Mortality following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08
47. Nomogram for Predicting Risk of Cystectomy or Recurrence after Bladder Preserving Trimodality Therapy for Muscle Invasive Bladder Cancer
48. 536 oral RTOG 9601: SALVAGE RT & ANTI-ANDROGEN THERAPY IN PROSTATE CANCER PATIENTS WITH ELEVATED PSA AFTER SURGERY
49. Prostatectomy or watchful waiting in prostate cancer [1] (multiple letters)
50. Long-term QOL Outcome after Proton Radiation for Localized Prostate Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.